Skip to Content Facebook Feature Image

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases

Business

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases
Business

Business

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases

2024-08-27 13:28 Last Updated At:13:45

HONG KONG, Aug. 27, 2024 /PRNewswire/ -- A research team led by Hong Kong Baptist University (HKBU) has discovered that phosphocholine, an important component in the body's metabolism, could counteract the adverse effects of PM2.5 toxicity on lung cells. This discovery highlights the therapeutic potential of phosphocholine in treating lung diseases associated with PM2.5 such as asthma, chronic obstructive pulmonary disease and lung cancer, and contributes to developing health measures against air pollution.

The research findings have been published in the international academic journal Proceedings of the National Academy of Sciences.

PM2.5 increases health risks

The World Health Organisation has linked air pollution to an estimated seven million deaths annually, and recognising it as the leading environmental risk factor globally. PM2.5, a major air pollutant, increases the risk of health problems such as heart and lung diseases. Every type of PM2.5 component possesses distinct impacts on human health. However, the understanding of the toxicity effects of individual PM2.5 components remains limited, and the respective preventive solutions for PM2.5-associated health problems are lacking.

To understand the effects of different PM2.5 components on the underlying cell metabolism associated with lung diseases, a team led by Professor Cai Zongwei, Chair Professor of the Department of Chemistry and Director of the State Key Laboratory of Environmental and Biological Analysis, and Dr Yang Zhu, Assistant Professor of the Department of Biology at HKBU, analysed a total of 82 components in PM2.5 samples collected from Taiyuan in Shanxi Province and Guangzhou in Guangdong Province between 2017 and 2018.

It was found that the overall PM2.5 profiles were similar in both cities. Inorganic ions are the most abundant pollutants, followed by metals and organic compounds polycyclic aromatic hydrocarbons (PAHs). However, a large difference was observed in the relative proportions of PAHs and their derivatives.

PM2.5 composition contributes to toxicity

The research team discovered that the proportion of PAHs was significantly higher in Taiyuan, especially during the heating season. Since the abundance of PAHs is closely associated with coal combustion, the result suggested that coal combustion was one of the major sources of PM2.5 in the city. Conversely, the seasonal variance of PAHs in Guangzhou was significantly lower. Traffic emissions were the predominant PM2.5 in Guangzhou.

Given the disparity in pollutant composition, the research team conducted toxicity and health risk analysis of PM2.5 samples from both cities. A cytotoxicity test revealed that the PM2.5 from winter Taiyuan exhibited much stronger toxicity than the samples from Guangzhou or from other seasons of Taiyuan with the same PM2.5 concentration, as indicated by cell viability which measures the proportion of healthy living cells. Assessment using the incremental lifetime cancer risk model, which estimates increased cancer risk from carcinogen exposure, highlighted that the regional difference in cancer risks linked to PAHs and its derivatives nitro-PAHs' concentration was much higher than the variation in overall PM2.5 concentration. These findings underscore that PM2.5 toxicity cannot be solely attributed to its concentration but also to its composition.

Phosphocholine counteracts PM2.5 toxicity

The research team further employed correlation analysis to examine the impact of specific PM2.5 components on metabolic alterations in lung cells, and identified 11 metabolites that showed a significant correlation with PM2.5 components. Among these metabolites, the researchers focused on the functions of eight ones whose amount reduced significantly after PM2.5 exposure. Subsequent experiments demonstrated that only supplementing phosphocholine to PM2.5-exposed cells was effective in both rescuing cell viability and stimulating adenosine triphosphate (ATP) production. ATP is a critical molecule for energy storage, which provides the energy needed for a wide range of cellular processes within living cells.

Under normal circumstances, lung cells primarily rely on glucose for energy production. However, PM2.5 conditions might impair energy supply from glucose. Fatty acid oxidation is a process in cells that breaks down fatty acids to generate energy. Under normal conditions, the utilisation of fatty acid oxidation pathway contributes minimally to energy production in lung cells. It was found that phosphocholine can reprogramme cellular metabolism to increase fatty acid oxidation to meet the shortfall in energy supply during the PM2.5 challenge, which helps to alleviate cellular dysfunction induced by PM2.5.

Professor Cai said: "Our findings highlighted the potential of phosphocholine as a therapeutic agent for lung diseases associated with PM2.5. As air pollution caused by PM2.5 has been recognised as a significant global health risk factor, our discovery provides the prospect of developing novel treatments for related health issues, potentially helping to address this public health challenge."

In future, the research may also contribute to the development of diagnosis protocol for lung diseases caused by PM2.5 apart from its potential as a therapeutic agent.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases

Trader-first innovation recognised across FXT's all-in-one trading ecosystem.

SYDNEY, Nov. 10, 2026 /PRNewswire/ -- FXT has been named Most Innovative Broker 2026 in the global brokerage category at the Finance Magnates Awards, announced on 6 November in Limassol, Cyprus.

For FXT, the award marks more than technology. It celebrates a philosophy pursued since 2014: relentless innovation, Total Quality Management and the belief that every advancement should give traders more clarity, control and choice when markets move.

That philosophy shapes FXT's all-in-one trading ecosystem, connecting multi-asset CFD trading, MetaTrader platforms, FXT WebTrader, the FXT App trading experience and account tools. Rather than forcing traders to piece together disconnected services, FXT is building around their decisions and workflows.

At the centre is FXT AI, an in-house, multi-agent trading co-pilot integrated into the FXT client environment, not a generic AI plug-in. Its Market Reader, Trade Mentor and Risk Monitor are designed to bring market context, trading behaviour and open-position exposure into clearer view. FXT AI supports decision-making; traders remain in control.

FXT Social Trading extends that approach, connecting Strategy Providers and Followers within a dedicated copy-trading ecosystem. Together, these capabilities reflect innovation shaped around real trading needs, not technology for technology's sake.

"This is a proud moment for everyone at FXT. Our ambition has always been to put traders at the centre of the technology we build. Innovation and precision are not separate promises; they are the standards we work to every day," said CEO Adam Phillips.

The award provides momentum to FXT's brand belief: In Control. When It Gets Real. Because when markets become unpredictable, traders deserve tools built for the moments that matter.

About FXT
FXT is a global multi-asset forex and CFD broker built for traders who want greater clarity, control and choice when markets move. Since 2014, more than 100,000 traders worldwide have used FXT to access 200+ instruments across forex, indices, commodities and share CFDs. FXT supports trading through MT4, MT5, FXT WebTrader and the FXT Mobile App, with FXT AI built into the account experience.

FXT is a registered business name of Gleneagle Securities Pty Ltd, licensed by the Vanuatu Financial Services Commission under licence number 40256.

CFDs are leveraged products and carry a high risk of loss. Product availability, trading conditions and protections vary by jurisdiction and account type.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

FXT Named Most Innovative Broker at the 2026 Finance Magnates Awards

FXT Named Most Innovative Broker at the 2026 Finance Magnates Awards

Recommended Articles